Chapter

Fulvestrant in metastatic disease

Amit Agrawal, John F.R. Robertson and Kwok-Leung Cheung

in Endocrine Therapies in Breast Cancer

Published on behalf of Oxford University Press

ISBN: 9780199218141
Published online May 2011 | e-ISBN: 9780199606993 | DOI: http://dx.doi.org/10.1093/med/9780199218141.003.0005

Series: Oxford Oncology Library

Fulvestrant in metastatic disease

Show Summary Details

Preview

• Fulvestrant, a steroidal pure antioestrogen, has a unique mode of action on oestrogen receptor. • Clinically, it has been shown to be statistically non-inferior to anastrozole in two phase III trials leading to its licensing for clinical use. • It has also been shown to be statistically non-inferior to tamoxifen with efficacy being similar in oestrogen/progesterone receptor-positive patients in a double blind randomized trial. • It is clinical active in heavily pre-treated patients and does not preclude usage of further hormonal agents. • Presently available as monthly intramuscular formulation only, it has excellent tolerability profile with presently unclear activity on bone tissue.

Chapter.  4490 words.  Illustrated.

Subjects: Clinical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.